美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

F/m Emerald Life Sciences Innovation ETF

40.95

-1.0819-2.57%

盘后：41.200.2515+0.61%16:10 EDT

成交量：1,641

成交额：6.79万

市值：1.14亿

市盈率：- -

高：41.51

开：41.51

低：40.95

收：42.03

52周最高：48.78

52周最低：29.55

股本：277.70万

流通股本：277.70万

量比：1.26

换手率：0.06%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

科创板集成电路、创新药研发成果进入实质兑现期

中国经营报

Guardant Health Inc(GH)股票10月6日盘中下跌8.27%：背后推手曝光

TradingKey中文

Spyre Therapeutics因3.5亿美元股票发行而股价下跌

默克公司药物在皮肤病临床试验中取得成功，Spyre股价上涨

罗氏将早期肥胖症药物emugrobart从研发管线中剔除。

安进股价盘前大涨逾4%，受第三期临床试验结果提振。

诺和CEO释放并购信号，拟扩充药物研发管线

环球市场播报

公告精选︱科达制造：拟投资约45亿元建设年产50万吨石墨负极材料一体化项目；百花医药：不涉及创新药研发

创新药热度飙升，关注100%创新药研发标的

重发-第4次更新-美国卫生部长小肯尼迪向关键卫生委员会增补了八名新成员

Cogent Biosciences宣布FDA受理Bezuclastinib治疗晚期系统性肥大细胞增多症的新药申请

Guardant Health与Evernorth旗下Evicore达成协议，Shield血液检测自2027年1月1日起纳入结直肠癌筛查覆盖范围

阿斯利康股价盘后跌超2%，因其三期临床试验结果令人失望。

Spyre Therapeutics旗下Spy003疗法在第12周实现20%临床缓解率及30%内镜改善率

Guardant Health重磅里程碑：Guardant360® Cdx获FDA批准，成为阿斯利康Ectamah™（Camizestrant）晚期乳腺癌伴随诊断

Cogent Biosciences将向Hovione采购Bezuclastinib产品最低比例

Cogent Biosciences协议生效：为期五年，自动续约两年——SEC文件披露

美股异动丨诺华制药涨超7%，多发性硬化症口服药后期临床试验结果积极

药闻 | 英硅智能上市后首份半年报扭亏创新药研发加速拥抱AI

联环药业上半年扭亏为盈集采续采与创新药研发协同推进

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/LFSC/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":40.9485,"timestamp":1791921600000,"preClose":42.0304,"halted":0,"volume":1641,"hourTrading":{"tag":"盘后","latestPrice":41.2,"preClose":40.9485,"latestTime":"16:10 EDT","volume":1,"amount":40.9485,"timestamp":1791922205031,"change":0.2515,"changeRate":0.006142,"amplitude":0},"delay":0,"changeRate":-0.02574089230652093,"floatShares":2777035,"shares":2777035,"eps":0,"marketStatus":"未开盘","change":-1.0819,"latestTime":"10-13 16:00:00 EDT","open":41.505,"high":41.505,"low":40.9485,"amount":67907,"amplitude":0.01324,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791964800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":42.0304,"sharesOutstanding":2657035,"nav":42.06,"aum":116802092.1,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":41.2,"preClose":40.9485,"latestTime":"16:10 EDT","volume":1,"amount":40.9485,"timestamp":1791922205031,"change":0.2515,"changeRate":0.006142,"amplitude":0},"volumeRatio":1.264643},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2777035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.264643,"shares":2777035,"dividePrice":0,"high":41.505,"amplitude":0.01324,"preClose":42.0304,"low":40.9485,"week52Low":29.545,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":40.9485,"eps":0,"divideRate":0,"volume":1641,"delay":0,"ttmEps":0,"open":41.505,"prevYearClose":36.6147,"prevWeekClose":42.6071,"prevMonthClose":44.5697,"prevQuarterClose":44.5697,"fiveDayClose":42.1122,"twentyDayClose":45.3143,"sixtyDayClose":44.392},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673501811","title":"科创板集成电路、创新药研发成果进入实质兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2673501811","media":"中国经营报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673501811?lang=zh_cn&edition=fundamental","pubTime":"2026-10-07 19:56","pubTimestamp":1791374163,"startTime":"0","endTime":"0","summary":"近期，科创板公司研发频传利好消息，从创新药的首例入组和新适应证获批，到集成电路的存储平台量产与核心芯片交付，越来越多成果转化为实实在在的创新产出，科创板硬科技企业正从“持续投入”走向“成果兑现”。集成电路板块多点突破，存储、端侧AI、模拟与车规芯片均有实质进展落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610073888922323.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610073888922323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PBE","IBB","WRND","KSTR","LFSC","159546","SBIO","BBP","XLVI","GSKH","GDOC","BK4585","BK4588","APXH","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673068734","title":"Guardant Health Inc(GH)股票10月6日盘中下跌8.27%：背后推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2673068734","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673068734?lang=zh_cn&edition=fundamental","pubTime":"2026-10-07 03:16","pubTimestamp":1791314179,"startTime":"0","endTime":"0","summary":"• 经过连续数月的反弹后，获利回吐导致 Guardant Health 股价下跌。\n• 持续亏损和高估值倍数引发了沉重的抛盘压力。\n• 该公司报告的年营收为 9.8202 亿美元，净利润为 -4.1628 亿美元。","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262202425-market-movers-gh-20261006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","LU0889565916.HKD","BK4535","LFSC","BK4551","GDOC","HELX","BK4196","EKG","FFOX","LU0109394709.USD","BK4585","GNMX","GH","BK4588","GNOM","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673055873","title":"Spyre Therapeutics因3.5亿美元股票发行而股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2673055873","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673055873?lang=zh_cn&edition=fundamental","pubTime":"2026-10-06 19:16","pubTimestamp":1791285402,"startTime":"0","endTime":"0","summary":"BUZZ-Spyre Therapeutics因3.5亿美元股票发行而股价下跌10月6日-** Spyre Therapeutics（SYRE.O）股价在盘前交易中下跌4.1%，报88.90美元，此前该公司定价完成了一笔3.5亿美元的后续融资** 这家生物技术公司于周一晚间宣布 (link)，以每股85美元的价格发行约410万股，较最后成交价折让8.3%** 该公司计划将募集资金净额用于推进其胃肠","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nL4S45S0QN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035773651.USD","LU2236285917.USD","LU0859254822.USD","BMED","LU1116320737.USD","IE00BN8TJ469.HKD","IXJ","LU0211331839.USD","LU0265550359.USD","LU1066051498.USD","HRTS","LU0689626769.HKD","SG9999014559.SGD","IE000M9KFDE8.USD","LU0266013472.USD","IE00BLSP4452.SGD","LU0320765646.SGD","LU0477156953.USD","LU0511384066.AUD","LU1923622614.USD","IE00BBT3K403.USD","LU0058720904.USD","LU1162221912.USD","LU1066051811.HKD","LU2324357040.USD","LU0289739343.SGD","LU0234572021.USD","LU0098860793.USD","BK4516","LU1037948897.HKD","IE00BSNM7G36.USD","LU2417539215.USD","LU1066051225.USD","IE00B1BXHZ80.USD","BK4585","SG9999001176.USD","LU0070302665.USD","LU0130517989.USD","LU0320765489.SGD","LU0868494708.USD","LU1291159041.SGD","LU0122379950.USD","LU1116320901.HKD","LU2023250843.SGD","LU0072461881.USD","IHE","LU0985320562.USD","IE00BJT1NW94.SGD","LU2360032135.SGD","LU2491049909.HKD","LU1023059063.AUD","LU1934455277.USD","GDOC","LU2361045086.USD","SG9999001440.SGD","LU0965509101.SGD","LU0265550946.USD","LU2461242641.AUD","LU0057025933.USD","LU2433249047.HKD","SG9999014542.SGD","MRK","LU2125909247.SGD","LU2357627491.SGD","LU2361044949.HKD","LU0823416689.USD","SG9999015358.SGD","LU1430594728.SGD","LU0130102774.USD","LU1934455863.HKD","LU2456880835.USD","LU0106261372.USD","LU0162691827.USD","LU2361044865.SGD","LU0965508806.USD","LU0289961442.SGD","LU0648001328.SGD","LU0203345920.USD","LU1571399168.USD","VHT","LU0203347892.USD","LU1929549753.HKD","RXL","LU1037948541.HKD","SG9999001176.SGD","IE0002141913.USD","LU1989771016.USD","LU0432979614.USD","TRUH","LU0238689110.USD","LU1069347547.HKD","FTXH","LU2112291526.USD","LU1057294990.SGD","LU2468319806.SGD","LU1201861249.SGD","PAWZ","LU0208291251.USD","SG9999014567.USD","LU2106854487.HKD","LU2491050154.USD","IE00BFTCPJ56.SGD","SG9999013999.USD","BK4559","LU0472753341.HKD","LU2125154935.USD","XLV","LU2023250504.SGD","SG9999015341.SGD","LU2125154778.USD","IE00BLSP4239.USD","LU0006306889.USD","IE00B4R5TH58.HKD","LU0069063385.USD","BK4533","LU1032466523.USD","LU1699723380.USD","LU1917777945.USD","LFSC","LU1093756168.USD","IE00B2B36J28.USD","JDOC","LU1989772923.USD","LU0942090050.USD","BK4534","LU0861579265.USD","LU2089984988.USD","LU1934455194.USD","IE00BJJMRZ35.SGD","LU0868494617.USD","SGXZ57979304.SGD","LU2491050071.SGD","BK4550","IE0009355771.USD","LU1585245621.USD","SG9999002232.USD","LU1974910355.USD","PPH","LU0965509283.SGD","LU0124676726.USD","LU1989772840.SGD","BK4588","LU0965509010.AUD","LU1066053197.SGD","SG9999002224.SGD","LU0980610538.SGD","LU1941712348.USD","SYRE","LU1093756325.SGD","LU2125909593.SGD","LU1941712264.USD","LU1983299246.USD","FHLC","LU1061106388.HKD","SG9999014575.USD","IYH","BK4139","BK4007","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671678345","title":"默克公司药物在皮肤病临床试验中取得成功，Spyre股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2671678345","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671678345?lang=zh_cn&edition=fundamental","pubTime":"2026-09-30 23:00","pubTimestamp":1790780436,"startTime":"0","endTime":"0","summary":"BUZZ-默克公司药物在皮肤病临床试验中取得成功，Spyre股价上涨9月30日-** Spyre Therapeutics（SYRE.O）股价上涨6.08%，至89.87美元** 默克公司（MRK.N）的实验性药物tulisokibart可显著减轻患有慢性皮肤病“化脓性汗腺炎”（(link)）患者的炎症性皮肤病变** 分析师表示，该数据验证了TL1A类药物的有效性，并支持Spyre针对同一信号通路","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL4T45M1CW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","LU2361044949.HKD","LU1066051811.HKD","LU2360032135.SGD","SG9999013999.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0868494708.USD","BK4559","LU1037948897.HKD","LU1032466523.USD","LU2125909593.SGD","SG9999001176.SGD","LU1989772840.SGD","LU0942090050.USD","LU2023250843.SGD","SG9999001440.SGD","IHE","IE00BLSP4239.USD","FTXH","XLV","GDOC","LU0320765646.SGD","IYH","LU0069063385.USD","FHLC","LU0477156953.USD","VHT","LU0072461881.USD","BK4534","LU1917777945.USD","LU0868494617.USD","LU1066051498.USD","IE00BJT1NW94.SGD","LU2112291526.USD","HRTS","LU1035773651.USD","PAWZ","LU1989772923.USD","LU2468319806.SGD","SG9999014567.USD","SYRE","LU1934455277.USD","LU1023059063.AUD","LU1061106388.HKD","LU2361045086.USD","LU0006306889.USD","LU2433249047.HKD","SG9999014559.SGD","LU1162221912.USD","LU0162691827.USD","LU1585245621.USD","BK4139","BK4533","LU2023250504.SGD","LU0965509283.SGD","LU0070302665.USD","SG9999002224.SGD","IE00B2B36J28.USD","LU0265550359.USD","IE00BBT3K403.USD","IE00B1BXHZ80.USD","IE00BSNM7G36.USD","LU2125154935.USD","LU2491050071.SGD","BK4007","LU0289739343.SGD","IE00BN8TJ469.HKD","LU2361044865.SGD","LU2491049909.HKD","LU1941712348.USD","LU0320765489.SGD","LU0098860793.USD","LU1069347547.HKD","BK4588","LU2324357040.USD","LU1929549753.HKD","LU1989771016.USD","LU0823416689.USD","LU2491050154.USD","LU0289961442.SGD","LU0980610538.SGD","LU1093756168.USD","LU1066051225.USD","IE00BJJMRZ35.SGD","RXL","LU2089984988.USD","LU0965509010.AUD","LU0861579265.USD","LU0965508806.USD","MRK","LU1066053197.SGD","LU0432979614.USD","LU1037948541.HKD","LU0265550946.USD","LU0985320562.USD","LU1571399168.USD","LU1974910355.USD","LU0211331839.USD","LU0130517989.USD","LU0130102774.USD","LU0234572021.USD","SG9999014575.USD","LU0266013472.USD","BK4516","LU0689626769.HKD","IE00B4R5TH58.HKD","LU2461242641.AUD","LU2125154778.USD","LU1057294990.SGD","BK4550","LU1934455194.USD","SGXZ57979304.SGD","LU0511384066.AUD","LU1430594728.SGD","LU0058720904.USD","LU0472753341.HKD","SG9999002232.USD","BK4585","LU0122379950.USD","LU0965509101.SGD","PPH","JDOC","TRUH","LU1116320901.HKD","SG9999014542.SGD","LU1116320737.USD","BMED","LU0203347892.USD","LU0057025933.USD","LU0289739699.SGD","IE000M9KFDE8.USD","LU2106854487.HKD","LU0124676726.USD","LU0238689110.USD","LU2125909247.SGD","LU2357627491.SGD","LU0203345920.USD","SG9999015358.SGD","IE00BLSP4452.SGD","LU1201861249.SGD","LU1093756325.SGD","SG9999001176.USD","LU1983299246.USD","LU1941712264.USD","LU0208291251.USD","LU0648001328.SGD","LU1291159041.SGD","LU1923622614.USD","LFSC","SG9999015341.SGD","IE0009355771.USD","LU1934455863.HKD","IXJ","LU0859254822.USD","LU0106261372.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670280289","title":"罗氏将早期肥胖症药物emugrobart从研发管线中剔除。","url":"https://stock-news.laohu8.com/highlight/detail?id=2670280289","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670280289?lang=zh_cn&edition=fundamental","pubTime":"2026-09-28 16:45","pubTimestamp":1790585147,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114208","title":"安进股价盘前大涨逾4%，受第三期临床试验结果提振。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114208","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669114208?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 21:07","pubTimestamp":1790082475,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNY","XPH","XBIX","LU0109394709.USD","FTXH","AMGN","HELX","PBE","BBH","MRNX","PPH","CANC","BBP","AZNH","IBBQ","BK4585","RXL","LU2272731865.HKD","PBPH","SYNB","BME","GNOM","TBXU","IBRN","FBT","BIB","LU1992135472.HKD","LU2272731782.SGD","IEHS","LU2473716301.USD","LU2242646821.SGD","RSPH","WDNA","IE00B5TLWC47.USD","BIOY","BK4599","IE00B4R5TH58.HKD","LFSC","IEIH","PJP","IBB","LU0058720904.USD","MEDI","TMED","PSCH","LU0122379950.USD","SBIO","LU0320765992.SGD","IDNA","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669110902","title":"诺和CEO释放并购信号，拟扩充药物研发管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2669110902","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669110902?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 17:13","pubTimestamp":1790068380,"startTime":"0","endTime":"0","summary":"核心要点诺和诺德首席执行官迈克・杜斯达尔在接受采访时表示，面对日趋激烈的行业竞争，公司正在考量各类并购机会。2026 年 2 月 11 日（周三），美国纽约，诺和诺德首席执行官迈克・杜斯达尔接受采访。这家制药巨头正身处竞争日趋白热化的减肥药赛道，CEO 迈克・杜斯达尔在采访中透露，公司正在评估并购机会。杜斯达尔周二做客《欧洲财经论谈》（Squawk Box Europe）节目时称：“我们会找出自身业务短板，去寻找那些已经研发出、或是即将推出比我们自研效果更佳药物的企业。如果并购能够补齐这些短板，我们对此抱有相当浓厚的兴趣。”","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-22/doc-inissyrc5623427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KCE","XMMO","CALF","BK4588","BK4585","LFSC","MYLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169682","title":"公告精选︱科达制造：拟投资约45亿元建设年产50万吨石墨负极材料一体化项目；百花医药：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169682","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169682?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 21:52","pubTimestamp":1789998737,"startTime":"0","endTime":"0","summary":"逸豪新材：拟定增募资不超过18亿元用于增资收购铭丰电子不低于78%股权","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6758003","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0102","BIOY","BK4585","BK0070","PBE","GSKH","IBB","BK0251","WRND","BK0155","GDOC","BBP","600499","BK0188","BK4588","600721","BK0216","XLVI","SETM","LFSC","APXH","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669137049","title":"创新药热度飙升，关注100%创新药研发标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2669137049","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669137049?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 13:55","pubTimestamp":1789970100,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-21/doc-inisqkzy8876594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","GDOC","BK4585","06978","WRND","LNGR","XLVI","IBBQ","BIOY","IBB","MEDX","159992","SBIO","BBP","GSKH","BK4588","APXH","PBE","LFSC","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668942109","title":"重发-第4次更新-美国卫生部长小肯尼迪向关键卫生委员会增补了八名新成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2668942109","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668942109?lang=zh_cn&edition=fundamental","pubTime":"2026-09-18 03:56","pubTimestamp":1789674961,"startTime":"0","endTime":"0","summary":"小肯尼迪已对多个联邦卫生咨询机构进行了重组，包括疾病控制与预防中心的疫苗咨询委员会——他在去年解散整个委员会后，重新任命了其成员。美国最高法院去年6月作出的一项裁决 ，确认了小肯尼迪对预防保健委员会的管辖权。该裁决后的11月会议因2025年政府停摆而未能举行。今年5月，小肯尼迪解除了该有影响力的工作组主席和副主席的职务。路透联系美国卫生与公众服务部时，该部拒绝就专家小组下次会议的日期置评。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nL4S4591O0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","GNOM","LU0889565916.HKD","HELX","EKG","BK4551","GNMX","LU0109394709.USD","PTH","GH","FFOX","BK4588","BK4585","LU0320765992.SGD","BK4535","BK4196","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168602224","title":"Cogent Biosciences宣布FDA受理Bezuclastinib治疗晚期系统性肥大细胞增多症的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1168602224","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168602224?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 20:01","pubTimestamp":1789473701,"startTime":"0","endTime":"0","summary":"Cogent Biosciences今日宣布，美国食品药品监督管理局已正式受理其针对Bezuclastinib的新药申请，该药物拟用于治疗晚期系统性肥大细胞增多症患者。因此，Cogent Biosciences此番取得的阶段性成果，无疑受到了医学界和投资圈的广泛关注。Bezuclastinib作为一种高选择性KIT D816V突变抑制剂，其设计初衷正是为了精准靶向驱动AdvSM等疾病的核心致病机制。随着NDA获得受理，后续的审评沟通及潜在的获批上市进程也将逐步展开，业界正持续跟踪该药物的监管动态与临床数据表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CANC","BK4505","COGT","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103100254","title":"Guardant Health与Evernorth旗下Evicore达成协议，Shield血液检测自2027年1月1日起纳入结直肠癌筛查覆盖范围","url":"https://stock-news.laohu8.com/highlight/detail?id=1103100254","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103100254?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 04:08","pubTimestamp":1789416490,"startTime":"0","endTime":"0","summary":"Guardant Health公司宣布，Evernorth旗下的Evicore已决定将其Shield血液检测纳入结直肠癌（CRC）筛查的承保范围。这项覆盖计划将于2027年1月1日正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU0889565916.HKD","GNOM","BK4551","EKG","LFSC","LU0109394709.USD","LU0320765992.SGD","BK4196","GDOC","BK4585","PTH","HELX","GH","GNMX","FFOX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股价盘后跌超2%，因其三期临床试验结果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_cn&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IYH","HELX","IE00B5TLWC47.USD","CANC","XBIX","LU2272731600.USD","PBE","LU2272731782.SGD","RXL","LU2322448791.USD","AZNH","LU2322448957.HKD","RSPH","WDNA","PSCH","SBIO","IBRN","BIOY","IEIH","LU1992135399.USD","IDNA","IBB","FTXH","BBP","PPH","BIB","BK4585","BBH","LU1992135472.HKD","MEDI","PBPH","BK4588","GNOM","LU2473716301.USD","MRNY","TMED","BME","FBT","LU2272731865.HKD","LFSC","SYNB","XPH","IEHS","PJP","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121233294","title":"Spyre Therapeutics旗下Spy003疗法在第12周实现20%临床缓解率及30%内镜改善率","url":"https://stock-news.laohu8.com/highlight/detail?id=1121233294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121233294?lang=zh_cn&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788868991,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics日前宣布，其研发管线中的关键候选药物Spy003在临床试验中交出了令人瞩目的阶段性答卷。数据显示，在接受治疗满12周的时间节点上，该疗法成功促成了20%的患者达到临床缓解状态，与此同时，30%的受试者在内镜检查中观察到了显著的病情改善迹象。这一成果不仅彰显了Spy003在疾病修饰层面的潜在威力，也为公司后续的注册性临床推进注入了强劲信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116354483","title":"Guardant Health重磅里程碑：Guardant360® Cdx获FDA批准，成为阿斯利康Ectamah™（Camizestrant）晚期乳腺癌伴随诊断","url":"https://stock-news.laohu8.com/highlight/detail?id=1116354483","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116354483?lang=zh_cn&edition=fundamental","pubTime":"2026-09-05 06:11","pubTimestamp":1788559873,"startTime":"0","endTime":"0","summary":"Guardant Health今日宣布，其Guardant360 Cdx液体活检产品已获得美国食品药品监督管理局的里程碑式批准，正式成为阿斯利康新型内分泌疗法Ectamah在晚期乳腺癌治疗中的伴随诊断工具。Guardant Health管理层在声明中表示，这一里程碑不仅是对公司技术实力的权威认可，更是对癌症患者个体化治疗承诺的有力践行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","LU0109394709.USD","FFOX","HELX","LU0320765992.SGD","BK4196","BK4588","BK4551","GH","BK4535","GDOC","LFSC","GNMX","LU0889565916.HKD","PTH","EKG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107575074","title":"Cogent Biosciences将向Hovione采购Bezuclastinib产品最低比例","url":"https://stock-news.laohu8.com/highlight/detail?id=1107575074","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107575074?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 04:14","pubTimestamp":1788380059,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc. 已通过SEC文件披露，计划向Hovione采购Bezuclastinib产品的指定最低比例份额。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","LFSC","COGT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126702774","title":"Cogent Biosciences协议生效：为期五年，自动续约两年——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1126702774","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126702774?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 04:13","pubTimestamp":1788379990,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc. 的某项协议已正式生效，其初始期限设定为五年。根据美国证券交易委员会（SEC）的备案文件，该协议条款中包含自动续约机制——每当五年期限届满，协议将自动延长两年。这一续约安排，为合作双方的长期关系提供了延续性预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","BK4139","LFSC","COGT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股异动丨诺华制药涨超7%，多发性硬化症口服药后期临床试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664521258?lang=zh_cn&edition=fundamental","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BBH","RXL","MEDX","XPH","IE0002141913.USD","LU2322448957.HKD","NVS","LU0211331839.USD","SBIO","HELX","MEDI","IE00BJJMRZ35.SGD","PBPH","IEIH","FTXH","IBB","BIOY","IE0009355771.USD","BBP","MRNY","BIB","PJP","IEHS","TMED","BME","PPH","CANC","MRNX","IE00BFTCPJ56.SGD","LU2473716301.USD","LFSC","SYNB","FBT","AZNH","BK4588","PBE","IDNA","BK4585","GNOM","LU0070302665.USD","LU2272731600.USD","PSCH","RSPH","WDNA","XBIX","IE00B4R5TH58.HKD","IBRN","IYH","IE00BJT1NW94.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"药闻 | 英硅智能上市后首份半年报扭亏 创新药研发加速拥抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_cn&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SBIO","BK4588","IPOS","VTHR","AIPO","BIOY","GDOC","WRND","CHAT","GSKH","BK4585","LFSC","APXH","BBP","PBE","QTOC","IBB","ARTY","AGIX","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"联环药业上半年扭亏为盈 集采续采与创新药研发协同推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_cn&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBB","BIOY","BK4588","BBP","LFSC","WRND","GDOC","BK4585","600513","XLVI","PBE","APXH","BK0239","SBIO","GSKH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}]}}